



Bamlanivimab Added as Texas Medicaid Benefit

What is New?

On December 3, 2020, Texas Medicaid added bamlanivimab as a benefit in response to the COVID-19 Emergency Use Authorization (EUA). As of November 9, 2020, the drug is allowed as a covered benefit. Below is billing information and requirements.

Procedure Code	Administration Code
Q0239 – bamlanivimab	M0239 – Administration of bamlanivimab

Requirements for Billing:

- **Place of service:** Outpatient
- **Diagnosis Code:** U07.1 (mild to moderate COVID-19)
- **Ages** 12 year old and up
- **Weight:** at least 40kg
- **Status:** High risk of progressing to severe COVID-19 or requiring hospitalization
- **What’s reimbursed:** The federal government is currently purchasing bamlanivimab. It's providing bamlanivimab to states to distribute to health care providers at no cost for COVID-19 treatment. We won't reimburse for bamlanivimab that providers received for free. Providers should not charge members for the treatment. We will **reimburse for the administration of the treatment**. Other medically necessary treatment for COVID-19 will be covered consistent with the terms of the member's benefit plan. When providers begin to purchase bamlanivimab, we will update our position.

Have questions:

Contact our BCBSTX Medicaid Provider Service Center at 1-877-560-8055 or contact your BCBSTX Medicaid Provider Network Representative at 1-855-212-1615.